Clinical Trial

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 225Ac-labeled LNC1011 for treating patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-05.
Status change: Recruiting → Active, Not Recruiting 2026-04-27
Trial Details
NCT Number NCT07117760
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Prostate Cancer
Enrollment 16 participants
Start Date 2025-04-22
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29